U.S. Markets closed

Kala Pharmaceuticals, Inc. (KALA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7710-0.0817 (-9.58%)
At close: 04:00PM EST
0.7999 +0.03 (+3.75%)
After hours: 07:32PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8527
Bid0.7500 x 1300
Ask0.8177 x 2200
Day's Range0.7631 - 0.8530
52 Week Range0.7500 - 9.9690
Avg. Volume1,277,175
Market Cap50.501M
Beta (5Y Monthly)0.31
PE Ratio (TTM)N/A
EPS (TTM)-2.0330
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
  • GlobeNewswire

    Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 13,500 shares of Kala Pharmaceuticals common stock to four new employees. The stock options were granted on December 15, 2021. The


    Towercrest Capital Management Buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, ...

    Newtown, PA, based Investment company Towercrest Capital Management (Current Portfolio) buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, Invesco S&P 500 Equal Weight ETF, Impel NeuroPharma Inc, Kala Pharmaceuticals Inc, sells Vanguard FTSE Emerging Markets ETF, International Business Machines Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Towercrest Capital Management.

  • Benzinga

    Kala Pharma Acquires Ocular Surface Disease-Focused Company

    View more earnings on KALASee more from BenzingaClick here for options trades from BenzingaBiophytis To Restart Recruitment In US Centers For COVID-19 TrialLexicon's Sotagliflozin Shows Benefits in Heart Failure, Blood Glucose Control© 2021 Benzinga does not provide investment advice. All rights reserved.